Helix Biopharma (HBPCF) Stock Price, News & Analysis

Company Overview

Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines.

Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth. The candidate has been evaluated in clinical development for cancers including pancreatic adenocarcinoma and non-small cell lung cancer.

Helix BioPharma is based in Canada and has historically focused its development activities on oncology programs intended for international clinical and commercial markets. As a development-stage biotechnology company, its operations and future prospects depend on the progress of its drug candidates through clinical testing, regulatory review and potential commercialization.

Key Stats

• Today's Range: $0.77 to $0.77
• 50-Day Range: $0.77 to $1.71
• 52-Week Range: $0.77 to $1.73
• Volume: N/A
• Average Volume: 10 shs
• Market Capitalization: $58.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 6/12/2026
• Today: 10/24/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:HBPCF
• CIK: N/A
• Web: www.helixbiopharma.com
• Phone: 905-841-2300
• Fax: 905-841-2244
• Employees: 7
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -21.61%
• Return on Assets: -17.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.45
• Quick Ratio: 0.45

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 5.13

Miscellaneous

• Outstanding Shares: 76,380,000
• Free Float: 70,573,000
• Market Cap: $58.81 million
• Optionable: Not Optionable
• Beta: 0.11